BIOTECH

Such an Opportunity May Never Come Again

The quality of projects developed in Polish laboratories is already appreciated by global giants. This is a unique opportunity for a win-win strategy between the Polish biotech sector and foreign investors

2022 was a landmark year for the Polish life sciences sector. The first drug developed in Polish laboratories was approved for the US market, and our scientific prowess was recognised by major international industry players, including BioNTech, Bio-Rad and Qiagen. Cash proceeds from the sale or licensing of Polish biotechnology innovations exceeded 1 billion PLN ‒ much more than total historical earnings combined.

Poland has everything it takes to develop advanced biomedical innovations: a strong academic base, educating thousands of high-level specialists every year; ingrained ambition and diligence; and strong support from public funds. It is also the only country in the region with a capital market extensively funding biotech innovation. However, there are many indications that ‒ especially given the current geopolitical situation ‒ without international financial investors taking an interest in the sector, domestic companies seeking to commercialise the results of their research might often find it a challenge. At the same time, this creates a unique investment opportunity for foreign capital.